Large-scale genomic screening of secreted proteins for therapeutic potential in diabetes reveals a surprise—bone morphogenetic protein-9.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chen, C. et al. Nat. Biotechnol. 21, 294–301 (2003).
Zimmet, P., Alberti, K.G. & Shaw, J. Nature 414, 782–787 (2001).
Bernard, C. Leçons de physiologie expérimentale appliquée a la médicine faites au collége de France. J. B. Baillieres, Paris, France (1855).
Lautt, W.W. Can. J. Physiol. Pharmacol. 77, 553–562 (1999).
Miller, A.F. et al. J. Biol. Chem. 275, 17937–17945 (2000).
López-Coviella, I. et al. Science 289, 313–316 (2000).
UK Prospective Diabetes Study 33. Lancet 352, 837–853 (1998).
Moller, D.E. Nature 414, 821–827 (2001).
Horikawa, Y. et al. Nat. Genet. 26, 163–175 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Groop, L. Bringing diabetes therapeutics to the big screen. Nat Biotechnol 21, 240–241 (2003). https://doi.org/10.1038/nbt0303-240
Issue Date:
DOI: https://doi.org/10.1038/nbt0303-240
This article is cited by
-
Potential roles of bone morphogenetic protein-9 in glucose and lipid homeostasis
Journal of Physiology and Biochemistry (2020)